Research digest · Common questions
PT-141 FAQ: the common questions, answered and cited.
Direct answers on what PT-141 is, what it is approved for, whether it works, and how it works — each cited to the literature where it makes a quantitative claim.
What is PT-141 used for?
PT-141 (bremelanotide) is FDA-approved as a subcutaneous injection for one use only: acquired, generalized HSDD in premenopausal women [3][6]. All other uses — in men, for erectile dysfunction, in postmenopausal women — are off-label and not supported by the approval. The male and erectile evidence is early-phase and investigational only.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of the natural hormone alpha-MSH that activates central melanocortin MC3R/MC4R receptors to influence sexual desire and arousal [1]. It is the same molecule the FDA approved in 2019 for HSDD in premenopausal women [6].
What is PT-141 peptide?
It is a melanocortin receptor agonist peptide: a seven-amino-acid ring (cyclic heptapeptide) closed by a lactam bridge, structurally related to alpha-MSH and to melanotan II, with molecular formula C50H68N14O10 and a molecular weight of 1025.2 Da [1]. The cyclic structure makes it more stable than a linear peptide.
What does the PT-141 peptide do?
It activates melanocortin receptors — chiefly MC4R — in hypothalamic and limbic brain circuits tied to sexual motivation, engaging dopaminergic pathways for appetitive sexual behavior [1][8]. It works on the brain's desire circuitry rather than on vascular blood flow, which is what distinguishes it from PDE-5 inhibitors.
Is PT-141 the same as bremelanotide?
Yes. "Bremelanotide" is the international nonproprietary name (INN) for the molecule; "PT-141" is the older research designation for the same melanocortin receptor agonist [6]. They name one compound, not two.
What is bremelanotide?
Bremelanotide is the FDA-approved melanocortin (MC3R/MC4R) receptor agonist, approved in June 2019 (NDA 210557) as a 1.75 mg subcutaneous injection for HSDD in premenopausal women [6]. It is the same compound studied as PT-141 [1].
Does PT-141 work?
In the two RECONNECT trials (n=1267) the coprimary endpoints were met: a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35) and reduced desire-related distress (FSDS-DAO item 13 -0.33) versus placebo [3]. The benefit is statistically real but clinically modest, and critical re-analyses have argued the effect is small.
How does PT-141 work?
It activates central melanocortin receptors, chiefly MC4R (and MC3R), in the hypothalamus and limbic system [1]. By stimulating MC4R in circuits such as the medial preoptic area it engages dopaminergic pathways governing sexual desire — a central mechanism, unlike PDE-5 inhibitors that act peripherally on vascular smooth muscle [1].
What receptors does PT-141 act on?
Primarily the melanocortin 4 receptor (MC4R) and, secondarily, the melanocortin 3 receptor (MC3R) — both central-nervous-system subtypes [1]. MC1R activation in the periphery accounts for the hyperpigmentation seen with repeated dosing [4].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on melanocortin circuits governing sexual motivation, which is mechanistically distinct from PDE-5 inhibitors that act peripherally on vascular smooth muscle to improve blood flow [1]. The fMRI work in women with HSDD supports the central account [5].
What is a melanocortin receptor agonist?
A compound that activates one or more of the five melanocortin receptors (MC1R-MC5R), which normally respond to peptides such as alpha-MSH [1]. PT-141 is a synthetic analogue of alpha-MSH targeting the central MC3R/MC4R subtypes [1].
Does PT-141 increase testosterone?
No. A common misconception is that PT-141 works hormonally; it does not act via the HPG axis and does not directly raise testosterone [1]. Its effect is mediated by central melanocortin (MC3R/MC4R) signaling in the brain, not by changing circulating hormone levels.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors (sildenafil, tadalafil) act peripherally on vascular smooth muscle to improve erectile blood flow [1]. PT-141 acts centrally on melanocortin circuits that govern sexual desire and arousal — a different target and a different mechanism. They address different parts of the problem.
What were the results of the PT-141 clinical trials?
Two identical Phase 3 RCTs (RECONNECT, n=1267 premenopausal women with HSDD) found bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints over 24 weeks [3]; a 52-week open-label extension (684 women) sustained the desire improvement with no new safety signals, the most common drug-related events being nausea (40.4%), flushing (20.6%), and headache (12.0%) [4].
What does PT-141 do for women?
It is the approved treatment for premenopausal women with acquired, generalized HSDD [3][6]. Mechanistic fMRI work in 31 women with HSDD showed MC4R agonism increased sexual desire for up to 24 hours and altered brain processing of erotic stimuli, consistent with a central rather than blood-flow mechanism [5].
How does PT-141 compare to flibanserin and testosterone for women?
Bremelanotide is an as-needed subcutaneous melanocortin agonist, whereas flibanserin (the other approved HSDD medication) is a daily oral drug, and testosterone is used off-label for some postmenopausal women [3]. Recent comparative reviews contrast their differing effect and tolerability profiles for female sexual dysfunction; the choice is a clinical one.
What is the PT-141 dosage?
The approved label specifies 1.75 mg subcutaneously, as needed, no more than one dose per 24 hours and no more than eight per month, for premenopausal women with HSDD [6]. Early intranasal male-ED research used much higher doses (escalation to ~7-20 mg) [7]. These are reported as trial and label figures, not dosing instructions.
What is the PT-141 dosage for women?
In the RECONNECT Phase 3 trials and the US label, the studied and approved figure for premenopausal women with HSDD is 1.75 mg subcutaneously, as needed, at least 45 minutes before anticipated activity, with no more than one dose per 24 hours and no more than eight per month [6]. This is a trial and label finding, not a protocol to follow.
How much PT-141 should I take?
This site does not recommend a dose for any individual. As a reported finding, the approved label for premenopausal women with HSDD specifies 1.75 mg subcutaneously, as needed, no more than one dose per 24 hours and no more than eight per month [6]. Any use is a matter for a qualified clinician, not a protocol to copy.
How much PT-141 to inject?
The single approved injection figure reported in the label and the RECONNECT trials is 1.75 mg subcutaneously, as needed [3][6]. That describes what was studied and approved for premenopausal women with HSDD, reported here as a finding rather than as guidance to self-administer.
How do you reconstitute PT-141?
The approved bremelanotide product is supplied as a ready-to-use prefilled subcutaneous autoinjector, so it is not reconstituted [6]. Reconstitution questions arise only for unapproved "research chemical" lyophilized powder, which is for laboratory use only and is not the approved finished drug; this site offers no preparation protocol.
How do you take PT-141?
In the trials and the approved label, bremelanotide was self-administered as a single subcutaneous injection, as needed, at least 45 minutes before anticipated activity, with strict per-day and per-month limits [6]. This describes the studied and approved route, reported as a finding, not as instructions for a reader to follow.